Sagimet Biosciences Inc. (SGMT)
3.45
-0.26 (-7.13%)
At close: Mar 03, 2025, 3:59 PM
3.51
1.68%
After-hours: Mar 03, 2025, 05:31 PM EST
No 1D chart data available
| Bid | 3.09 |
| Market Cap | 105.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.8M |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | -8.85 |
| Forward PE | -1.31 |
| Analyst | Buy |
| Ask | 3.93 |
| Volume | 546,702 |
| Avg. Volume (20D) | 1,000,368 |
| Open | 3.74 |
| Previous Close | 3.71 |
| Day's Range | 3.45 - 3.84 |
| 52-Week Range | 2.39 - 7.41 |
| Beta | 2.62 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2023
Employees 8
Stock Exchange NASDAQ
Ticker Symbol SGMT
Website https://sagimet.com
Analyst Forecast
According to 7 analyst ratings, the average rating for SGMT stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 769.04% from the latest price.
Buy 85.71%
Hold 14.29%
Sell 0.00%
1 month ago
+10%
Sagimet Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
3 months ago
-13.95%
Sagimet Biosciences shares are trading lower after the company reported worse-than-expected Q3 EPS results.
